GGrantIndex
← Search

A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLACT

$112,819M01FY2006RRNIH

Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center, Torrance CA

Investigators

Linked publications & trials

View original record on NIH RePORTER →